Linagliptin Reduces Effects of ET-1 and TLR2-mediated Cerebrovascular Hyperreactivity in Diabetes

Overview

Journal Life Sci

Publisher Elsevier

Specialties Biochemistry
Biology
Physiology

Date 2016 Feb 23

PMID 26898123

Citations 7

Authors

Trevor Hardigan

Yasir Abdul

Adviye Ergul

Affiliations

Soon will be listed here.

Abstract

Aims: The anti-hyperglycemic agent linagliptin, a dipeptidyl peptidase-4 inhibitor, has been shown to reduce inflammation and improve endothelial cell function. In this study, we hypothesized that DPP-IV inhibition with linagliptin would improve impaired cerebral blood flow in diabetic rats through improved insulin-induced cerebrovascular relaxation and reversal of pathological cerebrovascular remodeling that subsequently leads to improvement of cognitive function.

Main Methods: Male type-2 diabetic Goto-Kakizaki (GK) and nondiabetic Wistar rats were treated with linagliptin, and ET-1 plasma levels and dose response curves to ET-1 (0.1-100nM) in basilar arteries were assessed. The impact of TLR2 antagonism on ET-1 mediated basilar contraction and endothelium-dependent relaxation to acetylcholine (ACh, 1nM-1M) in diabetic GK rats was examined with antibody directed against the TLR2 receptor (Santa Cruz, 5μg/mL). The expression of TLR2 in middle cerebral arteries (MCAs) from treated rats and in brain microvascular endothelial cells (BMVEC) treated with 100nM linagliptin was assessed.

Key Findings: Linagliptin lowered plasma ET-1 levels in diabetes, and reduced ET-1-induced vascular contraction. TLR2 antagonism in diabetic basilar arteries reduced ET-1-mediated cerebrovascular dysfunction and improved endothelium-dependent vasorelaxation. Linagliptin treatment in the BMVEC was able to reduce TLR2 expression in cells from both diabetic and nondiabetic rats.

Conclusions: These results suggest that inhibition of DPPIV using linagliptin improves the ET-1-mediated cerebrovascular dysfunction observed in diabetes through a reduction in ET-1 plasma levels and reduced cerebrovascular hyperreactivity. This effect is potentially a result of linagliptin causing a decrease in endothelial TLR2 expression and a subsequent increase in NO bioavailability.

Citing Articles

Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications.

Yang D, Wang M, Zhang C, Wang Y Front Endocrinol (Lausanne). 2024; 15:1359255.

PMID: 38645427 PMC: 11026568. DOI: 10.3389/fendo.2024.1359255.

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging.

Cao F, Wu K, Zhu Y, Bao Z Front Endocrinol (Lausanne). 2021; 12:731273.

PMID: 34489872 PMC: 8416540. DOI: 10.3389/fendo.2021.731273.

Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation.

Cuijpers I, Papageorgiou A, Carai P, Herwig M, Mugge A, Klein T J Cell Mol Med. 2020; 25(2):729-741.

PMID: 33295687 PMC: 7812306. DOI: 10.1111/jcmm.16122.

Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases.

Wicinski M, Gorski K, Walczak M, Wodkiewicz E, Slupski M, Pawlak-Osinska K Int J Mol Sci. 2019; 20(16).

PMID: 31434198 PMC: 6719127. DOI: 10.3390/ijms20164052.

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.

Nakaoku Y, Saito S, Yamamoto Y, Maki T, Takahashi R, Ihara M Int J Mol Sci. 2019; 20(10).

PMID: 31126115 PMC: 6566831. DOI: 10.3390/ijms20102539.

References

Takata S, Sawa Y, Uchiyama T, Ishikawa H . Expression of Toll-Like Receptor 4 in Glomerular Endothelial Cells under Diabetic Conditions. Acta Histochem Cytochem. 2013; 46(1):35-42. PMC: 3596605. DOI: 10.1267/ahc.13002. View

Takahashi K, Ghatei M, Lam H, OHalloran D, Bloom S . Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990; 33(5):306-10. DOI: 10.1007/BF00403325. View

Cordero O, Salgado F, Nogueira M . On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58(11):1723-47. PMC: 11031058. DOI: 10.1007/s00262-009-0728-1. View

Abdelsaid M, Ma H, Coucha M, Ergul A . Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes. Life Sci. 2014; 118(2):263-7. PMC: 4096617. DOI: 10.1016/j.lfs.2013.12.231. View

Devaraj S, Tobias P, Kasinath B, Ramsamooj R, Afify A, Jialal I . Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol. 2011; 31(8):1796-804. PMC: 3148786. DOI: 10.1161/ATVBAHA.111.228924. View

Li W, Sachidanandam K, Ergul A . Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes. Neurol Res. 2011; 33(2):185-91. PMC: 3725271. DOI: 10.1179/016164111X12881719352417. View

Kalani M . The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag. 2009; 4(5):1061-8. PMC: 2605330. DOI: 10.2147/vhrm.s3920. View

Collier A, Leach J, McLellan A, Jardine A, Morton J, Small M . Plasma endothelinlike immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care. 1992; 15(8):1038-40. DOI: 10.2337/diacare.15.8.1038. View

Sachidanandam K, Hutchinson J, Elgebaly M, Mezzetti E, Dorrance A, Motamed K . Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1. Am J Physiol Regul Integr Comp Physiol. 2009; 296(4):R952-9. PMC: 2698601. DOI: 10.1152/ajpregu.90537.2008. View

10.

Abdelsaid M, Prakash R, Li W, Coucha M, Hafez S, Johnson M . Metformin treatment in the period after stroke prevents nitrative stress and restores angiogenic signaling in the brain in diabetes. Diabetes. 2014; 64(5):1804-17. PMC: 4407857. DOI: 10.2337/db14-1423. View

11.

Creager M, Luscher T, Cosentino F, Beckman J . Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108(12):1527-32. DOI: 10.1161/01.CIR.0000091257.27563.32. View

12.

Kroller-Schon S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R . Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012; 96(1):140-9. DOI: 10.1093/cvr/cvs246. View

13.

Ma J, Wu H, Zhao C, Panchapakesan U, Pollock C, Chadban S . Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int J Clin Exp Pathol. 2014; 7(2):481-95. PMC: 3925893. View

14.

Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A . Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012; 97(9):3333-41. PMC: 3431580. DOI: 10.1210/jc.2012-1544. View

15.

Schuit F, Huypens P, Heimberg H, Pipeleers D . Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes. 2001; 50(1):1-11. DOI: 10.2337/diabetes.50.1.1. View

16.

Ergul A . Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy. 2002; 22(1):54-65. DOI: 10.1592/phco.22.1.54.33505. View

17.

Alabadi J, Miranda F, Llorens S, Centeno J, Marrachelli V, Alborch E . Mechanisms underlying diabetes enhancement of endothelin-1-induced contraction in rabbit basilar artery. Eur J Pharmacol. 2004; 486(3):289-96. DOI: 10.1016/j.ejphar.2004.01.005. View

18.

Akash M, Rehman K, Chen S . Goto-Kakizaki rats: its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Curr Diabetes Rev. 2013; 9(5):387-96. DOI: 10.2174/15733998113099990069. View

19.

Arrick D, Sharpe G, Sun H, Mayhan W . Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase. Microvasc Res. 2006; 73(1):1-6. DOI: 10.1016/j.mvr.2006.08.001. View

20.

Ergul A, Abdelsaid M, Fouda A, Fagan S . Cerebral neovascularization in diabetes: implications for stroke recovery and beyond. J Cereb Blood Flow Metab. 2014; 34(4):553-63. PMC: 3982092. DOI: 10.1038/jcbfm.2014.18. View